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1. Introduction
As with all herpes viruses, cytomegalovirus (CMV) establishes a
latent infection in the host following recovery from an acute
infection. Activation from this latent state can occur with
immunosuppression, other illness, or the use of chemotherapeutic
agents. Clinical CMV disease can result from either a primary or a
secondary infection; in a primary infection, the virus usually
replicates to a higher level and the disease is more severe.
The role of CMV in inflammatory bowel disease (IBD) remains
controversial.1 Initial studies reported CMV inclusion bodies in
colectomy specimens from patients with fulminant or steroid-
refractory ulcerative colitis (UC).2 Other studies have questioned
the pathogenicity of CMV in active IBD by demonstrating a lack of
correlation of CMV and the clinical severity of IBD.3 However,
despite arguments on the non-pathogenicity of CMV reactivation,
the overall existing literature indicates that IBD patients are at
increased risk of CMV reactivation, and that the failure to
appropriately diagnose and treat these patients promptly leads
to significant morbidity and mortality. This increased risk is likely
multifactorial, due in part to both iatrogenic immunosuppression
and underlying factors related to severe inflammation, possible
malnutrition, and inherent immunogenicity.4 Although CMV
pneumonia may be a fatal disease in IBD patients,5 very little
information is available in the international literature on this issue
and CMV pneumonia was not mentioned in two recent reviews on
possible pulmonary complications during IBD.6,7
The objective of this review was to focus attention on this
potentially fatal disease, which we believe to be under-recognized,
at least in its initial manifestation, and to try to recognize those
characteristics of IBD patients that could be associated with CMV
pneumonia.
2. Methods
A computerized search without language restrictions was
conducted using PubMed and SCOPUS. The search was performed
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combining the terms (CMV OR cytomegalovirus OR ganciclovir)
AND (IBD OR Crohn OR ulcerative colitis OR inflammatory bowel
disease), without limits. Furthermore, all references listed were
hand-searched for other relevant articles. An article was consid-
ered eligible for inclusion in the systematic review if it reported
detailed data on patients with IBD who presented with pneumonia
due to CMV. CMV pneumonia was diagnosed in the presence of at
least: (1) positive radiology or autopsy findings of pneumonia, and
(2) pp65 antigenemia and/or CMV DNA in blood and/or positive
anti-CMV IgM and IgG titers, and (3) absence of other cause of
pneumonia. In the presence of another cause of pneumonia, the
detection of CMV inclusion bodies/immunohistochemical stain/
culture in biopsies/autopsy, or PCR on bronchoalveolar lavage
(BAL) fluid was considered necessary. The Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) guide-
lines were followed.8
3. Results
The PubMed search identified 387 publications, a scrupulous
analysis of which resulted in 13 eligible articles.5,9–20 One other
article (not present in PubMed) was found through the SCOPUS
search.21 Overall, 14 articles describing the history of 16 patients,
published between the years 1996 and 2011, were further
evaluated. A paper reporting two cases of CMV pneumonia but
lacking detailed information about the patients was excluded.19 A
case of UC with detectable circulating CMV DNA, in whom
respiratory symptoms were present but chest X-ray (performed
only once) was negative, was also excluded.20 A flow-diagram
summarizing the literature research approach is shown in Figure 1.
Data regarding the clinical characteristics, therapy, and
outcome of the 13 patients are given in Table 1. All patients were
adults with a mean age of 33 years (median age 28 years, range 18–
77 years), and 11/13 were females. Ten suffered from Crohn’s
disease (CD) and three from UC. The mean length of the IBD before
the appearance of respiratory symptoms was 8 years (median
duration 4.5 years, range 7 months–30 years). Five CD patients
came from Europe, four from North America, and one from
Australia.
Nine patients were under treatment with azathioprine (alone in
four cases and associated with 5-aminosalicylic acid, steroids, and/
or infliximab in the others), two patients were under treatment
with 6-mercaptopurine (in one case associated with steroids,
cyclosporine A, and 5-aminosalicylic acid), one patient was under
treatment with steroids and leukocytapheresis, and one was on
steroids plus cyclosporine A and 5-aminosalicylic acid. The mean
length of treatment with azathioprine before the appearance of
respiratory symptoms was 30 months and the median was 19
months.
Signs and symptoms were reported in all but two cases.13,16
Fever was present in 11 cases, dyspnea or reduced oxygen
saturation (SaO2) was reported in eight cases, cough in five cases,
Databases:  PubMed, 
[All Field s], No Li mit s
(CMV OR  cytomegalovirus OR  ganciclovir) AND (IBD 
OR Crohn OR  ulcerative colitis OR  inflamm atory bowel 
Databases: SCOPUS 
[Title, Abstract, Keywords] No  Li mits
(CMV OR  cytomegalovirus OR  ganciclovir) AND (IBD 
OR Crohn OR  ulcerative colitis OR  inflamm atory bowel 
disea se) disea se) 
Combined  sea rch result s, n =725
Articles  scree ned on  basis of title , abs tract, 
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Manuscript review and application of 
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CMV pneumonia)
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Figure 1. Flow of information through the different phases of the review.
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and chest pain in one case. Worsening dyspnea necessitating
mechanical ventilation was reported in eight cases. Normal breath
sounds at lung auscultation on patient admission were found in
four cases, basal crepitations in three cases, and in the remaining
cases auscultation results were not reported.
Radiological findings were described in all but one case.10
Diffuse bilateral infiltrates were described in nine cases. A mixed
but predominantly alveolar pattern was described in a case in
whom an Aspergillus fumigatus infection was also documented.12
Alveolar infiltrates were described in two cases in whom no other
cause of pneumonia was diagnosed. Chest X-ray performed at the
beginning of the disease failed to identify signs of pneumonia in
two cases.11,14
Methods used to diagnose CMV pneumonia were reported in all
but one case.16 Diagnosis was made by the detection of CMV
inclusion bodies/immunohistochemical stain/culture in biopsies/
autopsy in five cases,10–13,21 by polymerase chain reaction (PCR) on
bronchoalveolar lavage (BAL) fluid in three cases,15,18 by PCR on
peripheral blood in one case,17 by serology accompanied by a
positive pp65 antigenemia in one case,9 by a positive pp65
antigenemia later confirmed by autopsy in one case,5 and only by
serology in one case.14 Six cases were complicated by hemopha-
gocytic lymphohistiocytosis (HLH).9,15–18 In one other case with
severe anemia and thrombocytopenia who died due to acute
respiratory distress syndrome (ARDS), HLH was apparently not
diagnosed.5
Concomitant infections, one with Pneumocystis carinii (jiroveci)
and Nocardia species and another with Aspergillus fumigatus, were
diagnosed in two fatal cases.10,12 In all the other cases another
possible diagnosis of interstitial pneumonia was ruled out.
Azathioprine and 6-mercaptopurine were stopped in 7/9 and 2/
2 cases, respectively. Ganciclovir was used in 11 cases; in one case
no antiviral agent was used because the diagnosis was made post
mortem12 and in one case the pneumonia resolved without
antiviral treatment after the withdrawal of azathioprine.14
Ganciclovir was used alone or associated with foscarnet and/or
intravenous (IV) immunoglobulins (three cases). Oral valganci-
clovir was used after IV ganciclovir in two cases. Eight of the 13
cases were transferred to an intensive care unit and four of them
died.
4. Discussion
Analysis of the retrieved cases showed many interesting points,
including the gender distribution, IBD subtype, high fatality rates,
initial difficulties in diagnosis, possible complication with HLH,
and, finally, the best therapeutic approach.
The gender distribution in IBD has been investigated thorough-
ly in recent decades. Population-based studies have shown no
predominance of any sex in UC, whereas data from CD point to
slight differences, with female/male ratios that range from 1.1:1 to
2.2:1.22 These data do not explain the female/male ratio in our
series of 5.5:1. Several hypotheses may be considered to explain
this finding. First, women are more susceptible to CMV pneumo-
nia; second, women develop more severe forms that result in a
diagnosis; and third, younger women (the mean age in our series
was 33 years) may be more exposed to CMV through their children.
However no data on maternal status were reported in the retrieved
reports.
Concerning the disease subtype, CD was the underlying disease
in 77% of the cases. A possible explanation for this is that
immunosuppression is more common in CD compared to UC.
Eleven out of 13 (85%) patients retrieved in our review were on
treatment with thiopurines (nine with azathioprine and two with
6-mercaptopurine) when they developed CMV pneumonia.
Thiopurines can be considered a standard therapy for IBD
according to the most recent guidelines.23–26 However, it is
becoming apparent that compared to other immunomodulators/
biologicals typically used, thiopurines carry a disproportionately
higher risk of the reactivation of viral infections, beyond CMV,
including activating warts (human papillomavirus) with possible
resulting cervical dysplasia/cancer,27 and Epstein–Barr virus
leading to an increased risk of related lymphomas.28 Thus, for
fear of another future CMV reactivation, it is possible that
switching these patients from a thiopurine to an alternative
treatment after recovery from CMV pneumonia may be safer than
resuming the thiopurine.
CMV pneumonia is one of the most important opportunistic
infections in the immunocompromised host. Clinically, CMV
pneumonia usually shows an interstitial pattern, but nodules
may also be present on chest radiographic films. It is usually rapid
in onset, with respiratory symptoms of less than 2 weeks in
duration. Fever, nonproductive cough, and dyspnea that progresses
to hypoxia are common in severe cases. Hypoxia frequently
necessitates assisted mechanical ventilation.29 Since there is no
pathognomonic clinical finding in CMV pneumonia, BAL examina-
tion or transbronchial biopsy are generally required for diagnosis.
However, no consensus exists regarding the specific criteria for
establishing this diagnosis and to rule out potentially coexisting
opportunistic infections.30 Other causes of interstitial pneumonia
reported in IBD patients are: P. jiroveci, miliary tuberculosis,
varicella pneumonia, nocardiosis, histoplasmosis, influenza, ade-
novirus infection, Q fever, and legionellosis.31–41 Furthermore, in
cases of atypical pneumonia without a proven opportunistic
infection, azathioprine-associated interstitial pneumonitis may be
considered, which heals after withdrawal of the drug.42,43 The
chest X-ray was initially negative in two of the patients in this
study. This finding is not unusual in CMV pneumonia. A recent
paper has described a case in whom a chest CT scan was also
initially unremarkable.44
Finally, HLH was contextually present in six cases and was
probably triggered by the CMV infection. HLH is a potentially fatal
hyperinflammatory syndrome characterized by histiocyte prolif-
eration and hemophagocytosis. HLH may be inherited (primary,
familial), which occurs generally in infants, or may be secondary to
severe infection, malignancy, or a rheumatologic condition,
occurring at any age.45 HLH may cause systemic inflammatory
response syndrome, ARDS, and septic shock.46 Without treatment,
familial HLH is often rapidly fatal, and the reported mortality for
secondary HLH can exceed 50%. In the presence of cytopenia
(affecting two or more lineages in the peripheral blood) a diagnosis
of HLH should be suspected. However, the first assumption about a
patient with pancytopenia on azathioprine therapy is that the
pancytopenia is drug-related. Bone marrow suppression can occur
after a delay, but is reversible upon discontinuation of the drug.
The absence of severe bone marrow hypocellularity is evidence
against a direct role of azathioprine in the pancytopenia.9
From the analysis of our data we cannot extrapolate an
indication of the best treatment for CMV pneumonia. For patients
with CMV esophagitis, colitis, or rectal ulcers, improvement in
clinical symptoms is usually noted during the first week of therapy
with valganciclovir, ganciclovir, or foscarnet. In bone marrow
transplant recipients with CMV pneumonia, IV ganciclovir is
usually given concurrently with immune serum globulin or
hyperimmune globulin. However, there are no convincing data
to show that immune or hyperimmune globulin enhances efficacy.
As a result of this experience, immune serum globulin is often
administered to patients with HIV infection and suspected CMV
pneumonia as an adjunct to ganciclovir or foscarnet.30 The
duration of therapy is usually about 2 weeks, but this may be
extended to 3 weeks or longer in patients with severe disease or a
primary infection. In patients with CMV disease and viremia,
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therapy should be continued until resolution of CMV viremia,
because the risk of relapse is lower in patients who do not have
detectable CMV DNA after ganciclovir therapy.
This study has many limitations because the literature data on
this topic are few and heterogeneous. Epidemiological data on the
incidence of CMV pneumonia in patients with IBD cannot be
extrapolated. A prospective, structured, multicenter study would
be necessary to determine the real epidemiological scenario of this
potentially fatal complication.
In conclusion, CMV pneumonia should be suspected in IBD
patients who present fever and tachypnea, especially if the latter is
worsening and/or is associated with dyspnea. Chest X-ray should
be repeated if negative and CT may be advisable. CMV serology and
PCR in the blood should be performed, as well as a search for CMV
in BAL. While awaiting the virological results, we recommend the
prompt initiation of antiviral therapy. In the presence of cytopenia
(affecting two or more lineages in the peripheral blood) a diagnosis
of HLH should be suspected.
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